Podcast: Celltrion’s Subcutaneous Infliximab And The Future Of Biosimilars
We Discuss The Celltrion Product Breaking New Ground For Biosimilars
In this podcast discussion, Generics Bulletin’s David Wallace talks to Informa Pharma Consulting’s Duncan Emerton about Celltrion’s CHMP nod for subcutaneous Remsima, the product’s imminent approval and launch, and what it means for the future of biosimilars.
You may also be interested in...
Celltrion has pushed into another new market with its Remsima SC subcutaneous version of infliximab, launching the innovative biosimilar in Canada.
Health Canada has approved Celltrion’s subcutaneous version of Remsima for rheumatoid arthritis, as Celltrion plans to expand indications for the infliximab biosimilar to allow it to also treat inflammatory bowel disease. The company has also established an offshoot in Canada that will allow it to sell Remsima SC directly.
The European Commission has granted an extension to Celltrion’s pan-European marketing authorization for subcutaneous biosimilar infliximab, which now covers indications for IBD and ankylosing spondylitis.